November 16, 2026 · Blood · DOI: 10.1182/blood.2026034590

Etentamig in Relapsed/Refractory Multiple Myeloma: Pooled Phase 1 Data of an Investigational BCMA Bispecific Antibody.

Listen to this summary

This pooled analysis of phase 1 and phase 1b (Arm A) studies asks whether etentamig, a BCMA x CD3 bispecific T-cell engager with a low-affinity CD3 binder and FcRn-retained design, can deliver durable efficacy with a manageable safety profile and monthly dosing in heavily pretreated relapsed/refractory multiple myeloma. Among 146 patients with a median of 4 prior lines of therapy, objective response was 66% (≥VGPR 54%), with response duration and PFS not reached at a median follow-up of 13 months. Overall CRS was 30% (almost all Grade 1) with modified dexamethasone premedication and a single step-up dose, suggesting the design may reduce cytokine toxicity while supporting extended Q4W dosing.

Muhamed Baljevic, Peter Voorhees, Cesar Rodriguez, Anita D'Souza, Alfred Chung, Eben Isaac Lichtman, Hana Safah, Katja C Weisel, Ravi Vij, Hira Mian, Hila Magen, Emma Searle, John T Mckay, Neha S Korde, Saurabh Chhabra, Anders Svensson, Rajvineeth Kumar Pothacamury, Chetasi Talati, Carli Allendorf, Claudie Hecquet, Valerie Robinson, Aarif Ahsan, Shaji K Kumar

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play